Extend Biosciences’ D-VITylation platform technology improves the pharmacokinetic properties of peptide- and protein-based therapeutics. The technology is broadly applicable and feasibility studies have been completed on several distinct proof-of-concept molecules. Two candidate peptides are currently in IND-enabling studies.
The company is entering into strategic alliances with partners to assist in the discovery, development and commercialization of superior therapeutic peptides and proteins. These include the partner’s proprietary entities as well as those conjugates in Extend Biosciences’ own pipeline.
Please contact us for more information.